Inflammatory Pain Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034
The 7 major inflammatory pain markets reached a value of US$ 68.3 Billion in 2023. Looking forward, IMARC Group expects the 7MM to reach US$ 89.3 Billion by 2034, exhibiting a growth rate (CAGR) of 2.46% during 2024-2034.
The inflammatory pain market has been comprehensively analyzed in IMARC's new report titled "Inflammatory Pain Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034". Inflammatory pain refers to increased sensitivity that results from the natural response of the immune system to injury or infection. This condition can lead to the release of various chemical substances, such as prostaglandins, cytokines, histamines, etc., which sensitize the pain receptors and contribute to the perception of pain. It is often characterized by swelling, redness, heat, and pain in the affected area. The ailment can be categorized as acute or chronic. Acute inflammatory pain occurs suddenly and lasts for a short duration, whereas chronic inflammatory pain persists for weeks, months, or even years. The diagnosis of this illness involves a combination of medical history evaluation, physical examination, and diagnostic tests. Numerous blood workups, such as erythrocyte sedimentation rate, C-reactive protein, anti-cyclic citrullinated peptide antibody, etc., are recommended to assess the specific autoimmune or inflammation responsible for the disease. The healthcare provider may also perform various imaging techniques, like X-rays and ultrasound, to provide detailed images of the affected area that help in identifying signs of inflammation, damage, or structural abnormalities.
The increasing cases of tissue injuries due to cuts, burns, fractures, etc., which release certain chemical signals that trigger cytokine responses, are primarily driving the inflammatory pain market. In addition to this, the rising incidences of autoimmune disorders, leading to the accumulation of antigen-antibody complexes in joints, blood vessels, or various other organs, are also creating a positive outlook for the market. Moreover, the widespread adoption of non-steroidal anti-inflammatory drugs (NSAIDs), like ibuprofen, naproxen, aspirin, etc., that help to relieve pain and reduce discomfort associated with the ailment is further bolstering the market growth. Apart from this, the inflating application of physical therapy, owing to its several advantages, such as enhanced overall functional capacity, improved joint mobility, and promoted tissue healing, is acting as another significant growth-inducing factor. Additionally, the emerging popularity of transcutaneous electrical nerve stimulation techniques, which deliver low-voltage electrical currents through electrodes placed on the skin and help to reduce pain signals as well as provide symptom relief, is expected to drive the inflammatory pain market during the forecast period.
IMARC Group's new report provides an exhaustive analysis of the inflammatory pain market in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan. This includes treatment practices, in-market, and pipeline drugs, share of individual therapies, market performance across the seven major markets, market performance of key companies and their drugs, etc. The report also provides the current and future patient pool across the seven major markets. According to the report the United States has the largest patient pool for inflammatory pain and also represents the largest market for its treatment. Furthermore, the current treatment practice/algorithm, market drivers, challenges, opportunities, reimbursement scenario and unmet medical needs, etc. have also been provided in the report. This report is a must-read for manufacturers, investors, business strategists, researchers, consultants, and all those who have any kind of stake or are planning to foray into the inflammatory pain market in any manner.
Time Period of the Study
Base Year: 2023
Historical Period: 2018-2023
Market Forecast: 2024-2034
Countries Covered
United States
Germany
France
United Kingdom
Italy
Spain
Japan
Analysis Covered Across Each Country
Historical, current, and future epidemiology scenario
Historical, current, and future performance of the inflammatory pain market
Historical, current, and future performance of various therapeutic categories in the market
Sales of various drugs across the inflammatory pain market
Reimbursement scenario in the market
In-market and pipeline drugs
Competitive Landscape:
This report also provides a detailed analysis of the current inflammatory pain marketed drugs and late-stage pipeline drugs.
In-Market Drugs
Drug Overview
Mechanism of Action
Regulatory Status
Clinical Trial Results
Drug Uptake and Market Performance
Late-Stage Pipeline Drugs
Drug Overview
Mechanism of Action
Regulatory Status
Clinical Trial Results
Drug Uptake and Market Performance
*Kindly note that the drugs in the above table only represent a partial list of marketed/pipeline drugs, and the complete list has been provided in the report.
Key Questions Answered in this Report:
Market Insights
How has the inflammatory pain market performed so far and how will it perform in the coming years?
What are the markets shares of various therapeutic segments in 2023 and how are they expected to perform till 2034?
What was the country-wise size of the inflammatory pain market across the seven major markets in 2023 and what will it look like in 2034?
What is the growth rate of the inflammatory pain market across the seven major markets and what will be the expected growth over the next ten years?
What are the key unmet needs in the market?
Epidemiology Insights
What is the number of prevalent cases (2018-2034) of inflammatory pain across the seven major markets?
What is the number of prevalent cases (2018-2034) of inflammatory pain by age across the seven major markets?
What is the number of prevalent cases (2018-2034) of inflammatory pain by gender across the seven major markets?
How many patients are diagnosed (2018-2034) with inflammatory pain across the seven major markets?
What is the size of the inflammatory pain patient pool (2018-2023) across the seven major markets?
What would be the forecasted patient pool (2024-2034) across the seven major markets?
What are the key factors driving the epidemiological trend of inflammatory pain?
What will be the growth rate of patients across the seven major markets?
Inflammatory Pain: Current Treatment Scenario, Marketed Drugs and Emerging Therapies
What are the current marketed drugs and what are their market performance?
What are the key pipeline drugs and how are they expected to perform in the coming years?
How safe are the current marketed drugs and what are their efficacies?
How safe are the late-stage pipeline drugs and what are their efficacies?
What are the current treatment guidelines for inflammatory pain drugs across the seven major markets?
Who are the key companies in the market and what are their market shares?
What are the key mergers and acquisitions, licensing activities, collaborations, etc. related to the inflammatory pain market?
What are the key regulatory events related to the inflammatory pain market?
What is the structure of clinical trial landscape by status related to the inflammatory pain market?
What is the structure of clinical trial landscape by phase related to the inflammatory pain market?
What is the structure of clinical trial landscape by route of administration related to the inflammatory pain market?
The inflammatory pain market has been comprehensively analyzed in IMARC's new report titled "Inflammatory Pain Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034". Inflammatory pain refers to increased sensitivity that results from the natural response of the immune system to injury or infection. This condition can lead to the release of various chemical substances, such as prostaglandins, cytokines, histamines, etc., which sensitize the pain receptors and contribute to the perception of pain. It is often characterized by swelling, redness, heat, and pain in the affected area. The ailment can be categorized as acute or chronic. Acute inflammatory pain occurs suddenly and lasts for a short duration, whereas chronic inflammatory pain persists for weeks, months, or even years. The diagnosis of this illness involves a combination of medical history evaluation, physical examination, and diagnostic tests. Numerous blood workups, such as erythrocyte sedimentation rate, C-reactive protein, anti-cyclic citrullinated peptide antibody, etc., are recommended to assess the specific autoimmune or inflammation responsible for the disease. The healthcare provider may also perform various imaging techniques, like X-rays and ultrasound, to provide detailed images of the affected area that help in identifying signs of inflammation, damage, or structural abnormalities.
The increasing cases of tissue injuries due to cuts, burns, fractures, etc., which release certain chemical signals that trigger cytokine responses, are primarily driving the inflammatory pain market. In addition to this, the rising incidences of autoimmune disorders, leading to the accumulation of antigen-antibody complexes in joints, blood vessels, or various other organs, are also creating a positive outlook for the market. Moreover, the widespread adoption of non-steroidal anti-inflammatory drugs (NSAIDs), like ibuprofen, naproxen, aspirin, etc., that help to relieve pain and reduce discomfort associated with the ailment is further bolstering the market growth. Apart from this, the inflating application of physical therapy, owing to its several advantages, such as enhanced overall functional capacity, improved joint mobility, and promoted tissue healing, is acting as another significant growth-inducing factor. Additionally, the emerging popularity of transcutaneous electrical nerve stimulation techniques, which deliver low-voltage electrical currents through electrodes placed on the skin and help to reduce pain signals as well as provide symptom relief, is expected to drive the inflammatory pain market during the forecast period.
IMARC Group's new report provides an exhaustive analysis of the inflammatory pain market in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan. This includes treatment practices, in-market, and pipeline drugs, share of individual therapies, market performance across the seven major markets, market performance of key companies and their drugs, etc. The report also provides the current and future patient pool across the seven major markets. According to the report the United States has the largest patient pool for inflammatory pain and also represents the largest market for its treatment. Furthermore, the current treatment practice/algorithm, market drivers, challenges, opportunities, reimbursement scenario and unmet medical needs, etc. have also been provided in the report. This report is a must-read for manufacturers, investors, business strategists, researchers, consultants, and all those who have any kind of stake or are planning to foray into the inflammatory pain market in any manner.
Time Period of the Study
Base Year: 2023
Historical Period: 2018-2023
Market Forecast: 2024-2034
Countries Covered
United States
Germany
France
United Kingdom
Italy
Spain
Japan
Analysis Covered Across Each Country
Historical, current, and future epidemiology scenario
Historical, current, and future performance of the inflammatory pain market
Historical, current, and future performance of various therapeutic categories in the market
Sales of various drugs across the inflammatory pain market
Reimbursement scenario in the market
In-market and pipeline drugs
Competitive Landscape:
This report also provides a detailed analysis of the current inflammatory pain marketed drugs and late-stage pipeline drugs.
In-Market Drugs
Drug Overview
Mechanism of Action
Regulatory Status
Clinical Trial Results
Drug Uptake and Market Performance
Late-Stage Pipeline Drugs
Drug Overview
Mechanism of Action
Regulatory Status
Clinical Trial Results
Drug Uptake and Market Performance
*Kindly note that the drugs in the above table only represent a partial list of marketed/pipeline drugs, and the complete list has been provided in the report.
Key Questions Answered in this Report:
Market Insights
How has the inflammatory pain market performed so far and how will it perform in the coming years?
What are the markets shares of various therapeutic segments in 2023 and how are they expected to perform till 2034?
What was the country-wise size of the inflammatory pain market across the seven major markets in 2023 and what will it look like in 2034?
What is the growth rate of the inflammatory pain market across the seven major markets and what will be the expected growth over the next ten years?
What are the key unmet needs in the market?
Epidemiology Insights
What is the number of prevalent cases (2018-2034) of inflammatory pain across the seven major markets?
What is the number of prevalent cases (2018-2034) of inflammatory pain by age across the seven major markets?
What is the number of prevalent cases (2018-2034) of inflammatory pain by gender across the seven major markets?
How many patients are diagnosed (2018-2034) with inflammatory pain across the seven major markets?
What is the size of the inflammatory pain patient pool (2018-2023) across the seven major markets?
What would be the forecasted patient pool (2024-2034) across the seven major markets?
What are the key factors driving the epidemiological trend of inflammatory pain?
What will be the growth rate of patients across the seven major markets?
Inflammatory Pain: Current Treatment Scenario, Marketed Drugs and Emerging Therapies
What are the current marketed drugs and what are their market performance?
What are the key pipeline drugs and how are they expected to perform in the coming years?
How safe are the current marketed drugs and what are their efficacies?
How safe are the late-stage pipeline drugs and what are their efficacies?
What are the current treatment guidelines for inflammatory pain drugs across the seven major markets?
Who are the key companies in the market and what are their market shares?
What are the key mergers and acquisitions, licensing activities, collaborations, etc. related to the inflammatory pain market?
What are the key regulatory events related to the inflammatory pain market?
What is the structure of clinical trial landscape by status related to the inflammatory pain market?
What is the structure of clinical trial landscape by phase related to the inflammatory pain market?
What is the structure of clinical trial landscape by route of administration related to the inflammatory pain market?
1 PREFACE
2 SCOPE AND METHODOLOGY
2.1 Objectives of the Study
2.2 Stakeholders
2.3 Data Sources
2.3.1 Primary Sources
2.3.2 Secondary Sources
2.4 Market Estimation
2.4.1 Bottom-Up Approach
2.4.2 Top-Down Approach
2.5 Forecasting Methodology
3 EXECUTIVE SUMMARY
4 INFLAMMATORY PAIN - INTRODUCTION
4.1 Overview
4.2 Regulatory Process
4.3 Epidemiology (2018-2023) and Forecast (2024-2034)
4.4 Market Overview (2018-2023) and Forecast (2024-2034)
4.5 Competitive Intelligence
5 INFLAMMATORY PAIN - DISEASE OVERVIEW
5.1 Introduction
5.2 Symptoms and Diagnosis
5.3 Pathophysiology
5.4 Causes and Risk Factors
5.5 Treatment
6 PATIENT JOURNEY
7 INFLAMMATORY PAIN - EPIDEMIOLOGY AND PATIENT POPULATION
7.1 Epidemiology - Key Insights
7.2 Epidemiology Scenario - Top 7 Markets
7.2.1 Epidemiology Scenario (2018-2023)
7.2.2 Epidemiology Forecast (2024-2034)
7.2.3 Epidemiology by Age (2018-2034)
7.2.4 Epidemiology by Gender (2018-2034)
7.2.5 Diagnosed Cases (2018-2034)
7.2.6 Patient Pool/Treated Cases (2018-2034)
7.3 Epidemiology Scenario - United States
7.3.1 Epidemiology Scenario (2018-2023)
7.3.2 Epidemiology Forecast (2024-2034)
7.3.3 Epidemiology by Age (2018-2034)
7.3.4 Epidemiology by Gender (2018-2034)
7.3.5 Diagnosed Cases (2018-2034)
7.3.6 Patient Pool/Treated Cases (2018-2034)
7.4 Epidemiology Scenario - Germany
7.4.1 Epidemiology Scenario (2018-2023)
7.4.2 Epidemiology Forecast (2024-2034)
7.4.3 Epidemiology by Age (2018-2034)
7.4.4 Epidemiology by Gender (2018-2034)
7.4.5 Diagnosed Cases (2018-2034)
7.4.6 Patient Pool/Treated Cases (2018-2034)
7.5 Epidemiology Scenario - France
7.5.1 Epidemiology Scenario (2018-2023)
7.5.2 Epidemiology Forecast (2024-2034)
7.5.3 Epidemiology by Age (2018-2034)
7.5.4 Epidemiology by Gender (2018-2034)
7.5.5 Diagnosed Cases (2018-2034)
7.5.6 Patient Pool/Treated Cases (2018-2034)
7.6 Epidemiology Scenario - United Kingdom
7.6.1 Epidemiology Scenario (2018-2023)
7.6.2 Epidemiology Forecast (2024-2034)
7.6.3 Epidemiology by Age (2018-2034)
7.6.4 Epidemiology by Gender (2018-2034)
7.6.5 Diagnosed Cases (2018-2034)
7.6.6 Patient Pool/Treated Cases (2018-2034)
7.7 Epidemiology Scenario - Italy
7.7.1 Epidemiology Scenario (2018-2023)
7.7.2 Epidemiology Forecast (2024-2034)
7.7.3 Epidemiology by Age (2018-2034)
7.7.4 Epidemiology by Gender (2018-2034)
7.7.5 Diagnosed Cases (2018-2034)
7.7.6 Patient Pool/Treated Cases (2018-2034)
7.8 Epidemiology Scenario - Spain
7.8.1 Epidemiology Scenario (2018-2023)
7.8.2 Epidemiology Forecast (2024-2034)
7.8.3 Epidemiology by Age (2018-2034)
7.8.4 Epidemiology by Gender (2018-2034)
7.8.5 Diagnosed Cases (2018-2034)
7.8.6 Patient Pool/Treated Cases (2018-2034)
7.9 Epidemiology Scenario - Japan
7.9.1 Epidemiology Scenario (2018-2023)
7.9.2 Epidemiology Forecast (2024-2034)
7.9.3 Epidemiology by Age (2018-2034)
7.9.4 Epidemiology by Gender (2018-2034)
7.9.5 Diagnosed Cases (2018-2034)
7.9.6 Patient Pool/Treated Cases (2018-2034)
8 INFLAMMATORY PAIN - TREATMENT ALGORITHM, GUIDELINES, AND MEDICAL PRACTICES
8.1 Guidelines, Management and Treatment
8.2 Treatment Algorithm
9 INFLAMMATORY PAIN - UNMET NEEDS
10 INFLAMMATORY PAIN - KEY ENDPOINTS OF TREATMENT
11 INFLAMMATORY PAIN - MARKETED PRODUCTS
11.1 List of Inflammatory Pain Marketed Drugs Across the Top 7 Markets
11.1.1 Drug Name – Company Name
11.1.1.1 Drug Overview
11.1.1.2 Mechanism of Action
11.1.1.3 Regulatory Status
11.1.1.4 Clinical Trial Results
11.1.1.5 Sales Across Major Markets
Kindly note that the complete list of marketed drugs has been provided in the report.
12 INFLAMMATORY PAIN - PIPELINE DRUGS
12.1 List of Inflammatory Pain Pipeline Drugs Across the Top 7 Markets
12.1.1 GSK3858279 - GlaxoSmithKline
12.1.1.1 Drug Overview
12.1.1.2 Mechanism of Action
12.1.1.3 Clinical Trial Results
12.1.1.4 Safety and Efficacy
12.1.1.5 Regulatory Status
12.1.2 AFA281 - AfaSci
12.1.2.1 Drug Overview
12.1.2.2 Mechanism of Action
12.1.2.3 Clinical Trial Results
12.1.2.4 Safety and Efficacy
12.1.2.5 Regulatory Status
Kindly note that the above only represents a partial list of pipeline drugs, and the complete list has been provided in the report.
13. INFLAMMATORY PAIN - ATTRIBUTE ANALYSIS OF KEY MARKETED AND PIPELINE DRUGS
14. INFLAMMATORY PAIN – CLINICAL TRIAL LANDSCAPE
14.1 Drugs by Status
14.2 Drugs by Phase
14.3 Drugs by Route of Administration
14.4 Key Regulatory Events
15 INFLAMMATORY PAIN - MARKET SCENARIO
15.1 Market Scenario - Key Insights
15.2 Market Scenario - Top 7 Markets
15.2.1 Inflammatory Pain - Market Size
15.2.1.1 Market Size (2018-2023)
15.2.1.2 Market Forecast (2024-2034)
15.2.2 Inflammatory Pain - Market Size by Therapies
15.2.2.1 Market Size by Therapies (2018-2023)
15.2.2.2 Market Forecast by Therapies (2024-2034)
15.3 Market Scenario - United States
15.3.1 Inflammatory Pain - Market Size
15.3.1.1 Market Size (2018-2023)
15.3.1.2 Market Forecast (2024-2034)
15.3.2 Inflammatory Pain - Market Size by Therapies
15.3.2.1 Market Size by Therapies (2018-2023)
15.3.2.2 Market Forecast by Therapies (2024-2034)
15.3.3 Inflammatory Pain - Access and Reimbursement Overview
15.4 Market Scenario - Germany
15.4.1 Inflammatory Pain - Market Size
15.4.1.1 Market Size (2018-2023)
15.4.1.2 Market Forecast (2024-2034)
15.4.2 Inflammatory Pain - Market Size by Therapies
15.4.2.1 Market Size by Therapies (2018-2023)
15.4.2.2 Market Forecast by Therapies (2024-2034)
15.4.3 Inflammatory Pain - Access and Reimbursement Overview
15.5 Market Scenario - France
15.5.1 Inflammatory Pain - Market Size
15.5.1.1 Market Size (2018-2023)
15.5.1.2 Market Forecast (2024-2034)
15.5.2 Inflammatory Pain - Market Size by Therapies
15.5.2.1 Market Size by Therapies (2018-2023)
15.5.2.2 Market Forecast by Therapies (2024-2034)
15.5.3 Inflammatory Pain - Access and Reimbursement Overview
15.6 Market Scenario - United Kingdom
15.6.1 Inflammatory Pain - Market Size
15.6.1.1 Market Size (2018-2023)
15.6.1.2 Market Forecast (2024-2034)
15.6.2 Inflammatory Pain - Market Size by Therapies
15.6.2.1 Market Size by Therapies (2018-2023)
15.6.2.2 Market Forecast by Therapies (2024-2034)
15.6.3 Inflammatory Pain - Access and Reimbursement Overview
15.7 Market Scenario - Italy
15.7.1 Inflammatory Pain - Market Size
15.7.1.1 Market Size (2018-2023)
15.7.1.2 Market Forecast (2024-2034)
15.7.2 Inflammatory Pain - Market Size by Therapies
15.7.2.1 Market Size by Therapies (2018-2023)
15.7.2.2 Market Forecast by Therapies (2024-2034)
15.7.3 Inflammatory Pain - Access and Reimbursement Overview
15.8 Market Scenario - Spain
15.8.1 Inflammatory Pain - Market Size
15.8.1.1 Market Size (2018-2023)
15.8.1.2 Market Forecast (2024-2034)
15.8.2 Inflammatory Pain - Market Size by Therapies
15.8.2.1 Market Size by Therapies (2018-2023)
15.8.2.2 Market Forecast by Therapies (2024-2034)
15.8.3 Inflammatory Pain - Access and Reimbursement Overview
15.9 Market Scenario - Japan
15.9.1 Inflammatory Pain - Market Size
15.9.1.1 Market Size (2018-2023)
15.9.1.2 Market Forecast (2024-2034)
15.9.2 Inflammatory Pain - Market Size by Therapies
15.9.2.1 Market Size by Therapies (2018-2023)
15.9.2.2 Market Forecast by Therapies (2024-2034)
15.9.3 Inflammatory Pain - Access and Reimbursement Overview
16 INFLAMMATORY PAIN - RECENT EVENTS AND INPUTS FROM KEY OPINION LEADERS
17 INFLAMMATORY PAIN MARKET - SWOT ANALYSIS
17.1 Strengths
17.2 Weaknesses
17.3 Opportunities
17.4 Threats
18 INFLAMMATORY PAIN MARKET – STRATEGIC RECOMMENDATIONS
19 APPENDIX
2 SCOPE AND METHODOLOGY
2.1 Objectives of the Study
2.2 Stakeholders
2.3 Data Sources
2.3.1 Primary Sources
2.3.2 Secondary Sources
2.4 Market Estimation
2.4.1 Bottom-Up Approach
2.4.2 Top-Down Approach
2.5 Forecasting Methodology
3 EXECUTIVE SUMMARY
4 INFLAMMATORY PAIN - INTRODUCTION
4.1 Overview
4.2 Regulatory Process
4.3 Epidemiology (2018-2023) and Forecast (2024-2034)
4.4 Market Overview (2018-2023) and Forecast (2024-2034)
4.5 Competitive Intelligence
5 INFLAMMATORY PAIN - DISEASE OVERVIEW
5.1 Introduction
5.2 Symptoms and Diagnosis
5.3 Pathophysiology
5.4 Causes and Risk Factors
5.5 Treatment
6 PATIENT JOURNEY
7 INFLAMMATORY PAIN - EPIDEMIOLOGY AND PATIENT POPULATION
7.1 Epidemiology - Key Insights
7.2 Epidemiology Scenario - Top 7 Markets
7.2.1 Epidemiology Scenario (2018-2023)
7.2.2 Epidemiology Forecast (2024-2034)
7.2.3 Epidemiology by Age (2018-2034)
7.2.4 Epidemiology by Gender (2018-2034)
7.2.5 Diagnosed Cases (2018-2034)
7.2.6 Patient Pool/Treated Cases (2018-2034)
7.3 Epidemiology Scenario - United States
7.3.1 Epidemiology Scenario (2018-2023)
7.3.2 Epidemiology Forecast (2024-2034)
7.3.3 Epidemiology by Age (2018-2034)
7.3.4 Epidemiology by Gender (2018-2034)
7.3.5 Diagnosed Cases (2018-2034)
7.3.6 Patient Pool/Treated Cases (2018-2034)
7.4 Epidemiology Scenario - Germany
7.4.1 Epidemiology Scenario (2018-2023)
7.4.2 Epidemiology Forecast (2024-2034)
7.4.3 Epidemiology by Age (2018-2034)
7.4.4 Epidemiology by Gender (2018-2034)
7.4.5 Diagnosed Cases (2018-2034)
7.4.6 Patient Pool/Treated Cases (2018-2034)
7.5 Epidemiology Scenario - France
7.5.1 Epidemiology Scenario (2018-2023)
7.5.2 Epidemiology Forecast (2024-2034)
7.5.3 Epidemiology by Age (2018-2034)
7.5.4 Epidemiology by Gender (2018-2034)
7.5.5 Diagnosed Cases (2018-2034)
7.5.6 Patient Pool/Treated Cases (2018-2034)
7.6 Epidemiology Scenario - United Kingdom
7.6.1 Epidemiology Scenario (2018-2023)
7.6.2 Epidemiology Forecast (2024-2034)
7.6.3 Epidemiology by Age (2018-2034)
7.6.4 Epidemiology by Gender (2018-2034)
7.6.5 Diagnosed Cases (2018-2034)
7.6.6 Patient Pool/Treated Cases (2018-2034)
7.7 Epidemiology Scenario - Italy
7.7.1 Epidemiology Scenario (2018-2023)
7.7.2 Epidemiology Forecast (2024-2034)
7.7.3 Epidemiology by Age (2018-2034)
7.7.4 Epidemiology by Gender (2018-2034)
7.7.5 Diagnosed Cases (2018-2034)
7.7.6 Patient Pool/Treated Cases (2018-2034)
7.8 Epidemiology Scenario - Spain
7.8.1 Epidemiology Scenario (2018-2023)
7.8.2 Epidemiology Forecast (2024-2034)
7.8.3 Epidemiology by Age (2018-2034)
7.8.4 Epidemiology by Gender (2018-2034)
7.8.5 Diagnosed Cases (2018-2034)
7.8.6 Patient Pool/Treated Cases (2018-2034)
7.9 Epidemiology Scenario - Japan
7.9.1 Epidemiology Scenario (2018-2023)
7.9.2 Epidemiology Forecast (2024-2034)
7.9.3 Epidemiology by Age (2018-2034)
7.9.4 Epidemiology by Gender (2018-2034)
7.9.5 Diagnosed Cases (2018-2034)
7.9.6 Patient Pool/Treated Cases (2018-2034)
8 INFLAMMATORY PAIN - TREATMENT ALGORITHM, GUIDELINES, AND MEDICAL PRACTICES
8.1 Guidelines, Management and Treatment
8.2 Treatment Algorithm
9 INFLAMMATORY PAIN - UNMET NEEDS
10 INFLAMMATORY PAIN - KEY ENDPOINTS OF TREATMENT
11 INFLAMMATORY PAIN - MARKETED PRODUCTS
11.1 List of Inflammatory Pain Marketed Drugs Across the Top 7 Markets
11.1.1 Drug Name – Company Name
11.1.1.1 Drug Overview
11.1.1.2 Mechanism of Action
11.1.1.3 Regulatory Status
11.1.1.4 Clinical Trial Results
11.1.1.5 Sales Across Major Markets
Kindly note that the complete list of marketed drugs has been provided in the report.
12 INFLAMMATORY PAIN - PIPELINE DRUGS
12.1 List of Inflammatory Pain Pipeline Drugs Across the Top 7 Markets
12.1.1 GSK3858279 - GlaxoSmithKline
12.1.1.1 Drug Overview
12.1.1.2 Mechanism of Action
12.1.1.3 Clinical Trial Results
12.1.1.4 Safety and Efficacy
12.1.1.5 Regulatory Status
12.1.2 AFA281 - AfaSci
12.1.2.1 Drug Overview
12.1.2.2 Mechanism of Action
12.1.2.3 Clinical Trial Results
12.1.2.4 Safety and Efficacy
12.1.2.5 Regulatory Status
Kindly note that the above only represents a partial list of pipeline drugs, and the complete list has been provided in the report.
13. INFLAMMATORY PAIN - ATTRIBUTE ANALYSIS OF KEY MARKETED AND PIPELINE DRUGS
14. INFLAMMATORY PAIN – CLINICAL TRIAL LANDSCAPE
14.1 Drugs by Status
14.2 Drugs by Phase
14.3 Drugs by Route of Administration
14.4 Key Regulatory Events
15 INFLAMMATORY PAIN - MARKET SCENARIO
15.1 Market Scenario - Key Insights
15.2 Market Scenario - Top 7 Markets
15.2.1 Inflammatory Pain - Market Size
15.2.1.1 Market Size (2018-2023)
15.2.1.2 Market Forecast (2024-2034)
15.2.2 Inflammatory Pain - Market Size by Therapies
15.2.2.1 Market Size by Therapies (2018-2023)
15.2.2.2 Market Forecast by Therapies (2024-2034)
15.3 Market Scenario - United States
15.3.1 Inflammatory Pain - Market Size
15.3.1.1 Market Size (2018-2023)
15.3.1.2 Market Forecast (2024-2034)
15.3.2 Inflammatory Pain - Market Size by Therapies
15.3.2.1 Market Size by Therapies (2018-2023)
15.3.2.2 Market Forecast by Therapies (2024-2034)
15.3.3 Inflammatory Pain - Access and Reimbursement Overview
15.4 Market Scenario - Germany
15.4.1 Inflammatory Pain - Market Size
15.4.1.1 Market Size (2018-2023)
15.4.1.2 Market Forecast (2024-2034)
15.4.2 Inflammatory Pain - Market Size by Therapies
15.4.2.1 Market Size by Therapies (2018-2023)
15.4.2.2 Market Forecast by Therapies (2024-2034)
15.4.3 Inflammatory Pain - Access and Reimbursement Overview
15.5 Market Scenario - France
15.5.1 Inflammatory Pain - Market Size
15.5.1.1 Market Size (2018-2023)
15.5.1.2 Market Forecast (2024-2034)
15.5.2 Inflammatory Pain - Market Size by Therapies
15.5.2.1 Market Size by Therapies (2018-2023)
15.5.2.2 Market Forecast by Therapies (2024-2034)
15.5.3 Inflammatory Pain - Access and Reimbursement Overview
15.6 Market Scenario - United Kingdom
15.6.1 Inflammatory Pain - Market Size
15.6.1.1 Market Size (2018-2023)
15.6.1.2 Market Forecast (2024-2034)
15.6.2 Inflammatory Pain - Market Size by Therapies
15.6.2.1 Market Size by Therapies (2018-2023)
15.6.2.2 Market Forecast by Therapies (2024-2034)
15.6.3 Inflammatory Pain - Access and Reimbursement Overview
15.7 Market Scenario - Italy
15.7.1 Inflammatory Pain - Market Size
15.7.1.1 Market Size (2018-2023)
15.7.1.2 Market Forecast (2024-2034)
15.7.2 Inflammatory Pain - Market Size by Therapies
15.7.2.1 Market Size by Therapies (2018-2023)
15.7.2.2 Market Forecast by Therapies (2024-2034)
15.7.3 Inflammatory Pain - Access and Reimbursement Overview
15.8 Market Scenario - Spain
15.8.1 Inflammatory Pain - Market Size
15.8.1.1 Market Size (2018-2023)
15.8.1.2 Market Forecast (2024-2034)
15.8.2 Inflammatory Pain - Market Size by Therapies
15.8.2.1 Market Size by Therapies (2018-2023)
15.8.2.2 Market Forecast by Therapies (2024-2034)
15.8.3 Inflammatory Pain - Access and Reimbursement Overview
15.9 Market Scenario - Japan
15.9.1 Inflammatory Pain - Market Size
15.9.1.1 Market Size (2018-2023)
15.9.1.2 Market Forecast (2024-2034)
15.9.2 Inflammatory Pain - Market Size by Therapies
15.9.2.1 Market Size by Therapies (2018-2023)
15.9.2.2 Market Forecast by Therapies (2024-2034)
15.9.3 Inflammatory Pain - Access and Reimbursement Overview
16 INFLAMMATORY PAIN - RECENT EVENTS AND INPUTS FROM KEY OPINION LEADERS
17 INFLAMMATORY PAIN MARKET - SWOT ANALYSIS
17.1 Strengths
17.2 Weaknesses
17.3 Opportunities
17.4 Threats
18 INFLAMMATORY PAIN MARKET – STRATEGIC RECOMMENDATIONS
19 APPENDIX
